

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: M. Sakanaka, et al.

Serial No: 09/913,669

Group No.: 1623

Filed: August 16, 2001

Examiner: Khare, Devesh

For: CEREBROVASCULAR REGENERATION/RECONSTRUCTION PROMOTING
AGENTS AND SECONDARY NERVOUS TISSUE DEGENERATION-INHIBITING
AGENTS COMPRISING GINSENOSEIDE RB₁Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to Group 1600 of the U.S. Patent & Trademark Office by facsimile number 703-872-9306 on February 28, 2003.

By: 
John B. Alexander, Ph.D.RESPONSE

In response to the Office Action dated January 14, 2003, Applicants request reconsideration of the above-referenced application in view of the remarks below.

REMARKS

Claims 1, 2, 4-13, 15-24, and 28-31 stand rejected as being unpatentable under the doctrine of obviousness double patenting over claim 21, 24, 25, 28-34, 37, and 38 of allowed U.S. Patent Application No. 09/887,399. Although Applicants respectfully disagree with the stated basis of rejection, it will be addressed by submission of the Terminal Disclaimer.

In view thereof, reconsideration and withdrawal of the rejection are requested.